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Part I: Introduction 
Since 1984, the Food and Drug Administration (FDA) has approved over 8,000 generic 
drugs, which comprise approximately seventy-eight percent of currently filled prescriptions.1 
The Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act) has 
governed the approval of generic drugs.2 The Act provides an expedited approval process for 
generic drugs that have an identical Reference Listed Drug (RLD).  Provided a generic drug is 
the “same” as its listed drug counterpart, its manufacturer is permitted to forgo clinical testing, 
on the condition that the drug maintains the same label as the listed drug.3  The generic drug 
manufacturers have no authority to modify or update their own safety labels.4  The inability to 
independently update labels has led to issues concerning generic drug manufacturers’ liability for 
                                                          
1 Fact Sheet: New User Fees for Generic Drugs Will Enhance American’s Access to Less Expensive Drugs and 
Generate Major Cost Savings, http://www.fda.gov/RegulatoryInformation/Legislation/ 
FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDASIA/ucm310992.htm  (last 
visited Nov. 5,2014). 
2 See 21 U.S.C. 355(j) (1)-(2).  See also, Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-
Waxman Amendments) Before the S. Comm. on the Judiciary, (2003) (statement of Daniel E. Troy, Chief Counsel, 
U.S. Food and Drug Administration). 
3 Examining Concerns Regarding FDA’s Proposed Changes to Generic Drug Leveling Before the Energy and 
Commerce Subcomm. On Health, U.S. H.R., (2014) (statement of Ralph. G. Neas, President and CEO, The Generic 
Pharmaceutical Association).  
4 Id. 
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failure to warn of safety concerns, which have been recently addressed by the U.S. Supreme 
Court.5   
Congress has begun to address these concerns with the enactment of the Generic Drug 
User Fee Amendments of 2012 (“GDUFA”).6  The GDUFA recognizes the growth of the generic 
drug industry by expediting the approval process for generics, saving time and money for the 
industry, and ensuring Americans have access to low cost, quality medicine.  In exchange for 
faster approval times, the generic industry must pay user fees, as the branded pharmaceuticals 
do.7  The GDUFA is the beginning of major reform for the generic drug industry, placing some 
of the same obligations and benefits on the generic industry that the brand name manufacturers 
have. 
The growth of the generic industry and the issues presented in recent Supreme Court 
cases have prompted the FDA to reconsider current federal mandate and to suggest generic drug 
manufacturers be permitted to update their safety labels in response to safety issues that have 
been discovered.8  The proposed regulation would require generic-drug makers to update their 
labels in light of newly acquired safety information to avoid injury to consumers, which could 
result in legal liability.9  This Note argues that allowing generic-drug makers to update safety 
labels as soon as new information is received will increase patient safety and prevent injuries by 
                                                          
5 Jennifer M. Thomas, FDA Proposes a Rule that Would Undercut Generic Drug Preemption, FDA L. BLOG 
(September 2, 2014), http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2013/11/fda-proposes-a-rule-that-
would-undercut-generic-preemption.html   
6Food and Drug Administration Safety and Innovation Act, Pub. L. No. 112-144, §908, 126 Stat. 993 (2012). 
7 Fact Sheet, supra note 1. 
8 Joe Carlson, FDA’s Generic-Drug Label Rule Draws Controversy, MODERN HEALTHCARE (September 2, 2014), 
http://www.modernhealthcare.com/article/20140628/MAGAZINE/306289979. 
9 Id. 
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providing timely updates to safety information.10  This would also allow generic drugs that no 
longer have a brand-name counterpart to update their labels.11   
These changes may also have an impact on manufacturer’s exposure to failure-to-warn 
liability.  Under the Supreme Court’s 2011 ruling in PLIVA v. Mensing, generic drug makers are 
unable to add new side effect and safety information to product labeling and therefore should not 
be held accountable for any failure-to-warn claims.12  Currently, access to the courts depends on 
whether an individual has been prescribed a brand-name or generic drug.13  Many fear that if the 
proposed regulatory change is approved, it may allow consumers to file failure-to-warn claims 
against generic drug manufacturers.14  Once generic drug makers have the right to change their 
label, they are responsible for knowing the full effects of the drugs they produce, and may be 
sued for failing to timely update their labels.15  The FDA notice of the proposed rule 
acknowledges the proposed regulation may also change generic drug manufacturer’s liability.16  
Although the proposed regulations may have a significant impact on generic drug makers’ 
liability, such discussion is beyond the scope of this note. 
Part II of this Note will introduce background legislation and regulations concerning the 
labeling of brand-name and generic drugs.  It will describe the subsequent amendments to food 
                                                          
10 Id. 
11 Id. 
12 PLIVA, Inc. v. Mensing, 131 S. Ct. 2567 (2011); Silverman, Ed.  How Fast Should a Generic Drug Maker 
Update Labeling with New Safety Info? THE W.S.J. PHARMALOT, (Sept. 3, 2014), 
http://blogs.wsj.com/pharmalot/2014/09/03/how-fast-should-a-generic-drug-maker-update-labeling-with-new-
safety-info/; See also Mutual Pharm. Co. v. Bartlett, 133 S. Ct. 2466 (2013). 
13 Examining Concerns Regarding FDA’s Proposed Changes to Generic Drug Labeling Before S. Comm. On 
Health, Comm. On Energy and Commerce, U.S. H.R., (2014) (statement of Janet Woodcock, Director, Center for 
Drug Evaluation and Research, Food and Drug Administration, Department of Health and Human Service). 
14 Id. 
15 Carlson, supra note 8.  
16 Freidman, Ezra and Abraham L. Wickelgren.  Who (if Anyone) Should be Liable for Injuries from Generic Drugs? 
(citing 67986 Federal Register, Vol 78, No. 219, November 13, 2013. 
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and drug legislation in response to the growth of generic drugs over the past few decades.  Part II 
will also introduce the 2013 proposed regulatory amendments which would provide generic 
manufacturers the ability to independently update safety labels.  Part III of this Note will discuss 
the benefits of independent label changes to public policy and patient safety while keeping costs 
significantly lower than brand-name counterparts. 
Part II:  Background/Overview 
A. Statutory Background 
The Federal Food, Drug, and Cosmetic Act (“FD&C Act”) and the Public Health Service 
Act (“PHS Act”) “provide [the] FDA with authority over the labeling for drugs and biological 
products.”17  The Acts also authorizes the FDA to enact regulations to facilitate the review and 
approval of applications regarding the labeling for those products.”18  Section 502(f) of the 
FD&C Act states that “a product is misbranded unless its labeling bears adequate directions for 
use, including adequate warnings against, among other things, unsafe dosage, methods, duration 
of administration, or application.”19  Section 502(j) of the Act mandates that “a product is 
misbranded if it is dangerous to health when used in the manner prescribed, recommended, or 
suggested in its labeling.”20  These statutes created new standards for drug manufacturer’s 
products and facilities. 
In 1984, the FD&C Act was amended to include the Drug Competition and Patent Term 
Restoration Act, more commonly known as The Hatch-Waxman Act.21  The Hatch-Waxman Act 
                                                          
17 See 21 U.S.C. 301. See also 42 U.S.C. 201. 
18 Woodcock, supra note 13. 
19 Id. 
20 Id. 
21 Wolfman, Brian & Anne King, Mutual Pharmaceutical Co. v. Bartlett and Its Implications, U.S.L.W. (Sept. 19, 
2014), available at http://scholarship.law.georgetown.edu/facpub/1297. 
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provided a less stringent approval process for generic drug makers.  The generic manufacturer is 
now required to submit an abbreviated new drug application, showing the generic drug is the 
“same” as a previously approved brand-name drug, and the generic is “bioequivalent” to the 
brand name drug.22  Under the “sameness” requirement, the generic manufacturer must show that 
the generic drug provides the same safety and efficacy, by proving that the generic drug has the 
same active ingredient, is identical in strength, dosage and administration, and has the same 
safety label.23  The Act exempted generic manufacturers from the “expensive, time-consuming, 
and ultimately repetitive clinical testing and trials that already had been performed on the 
innovator drug.”24  In the twenty-two years preceding the Act, only fifteen generics had been 
approved by the FDA.  One year after the Act, more than 1,000 drugs approvals were submitted 
to the FDA.  The Act has resulted in billions of dollars of savings to the health care industry and 
consumers.25  
 Currently, for most substantive changes to drug labeling, a brand-name manufacturer 
must submit an approval supplement and obtain FDA approval for the change.26  FDA 
regulations also require manufacturers of pharmaceutical and biological products to submit 
reports of adverse drug experiences that occur after approval.27  In promotion of public health, 
the FDCA permits certain labeling changes based on newly acquired safety information about 
the drug when the manufacturer submits a “changes being effected” (“CBE-0”) supplement 
                                                          
22 Id. 
23 Neas, supra note 4. 
24 Id. 
25 Id. 
26 Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products, 78 Fed. 
Reg. 67985 (proposed Nov. 13, 2013), available at https://www.federalregister.gov/articles/2013/11/13/2013-
26799/supplemental-applications-proposing-labeling-changes-for-approved-drugs-and-biological-products 
27 Id. 
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describing the change.28  Newly acquired safety information is defined by the FDCA as 
"information derived from a clinical trial, an adverse event report, a post approval study . . .  peer 
reviewed biomedical literature, data derived from the post-market risk identification and analysis 
system under section 505(k); or other scientific data deemed appropriate by [the FDA]."29  When 
this information is received, the brand drug must update their warnings labels to reflect the new 
information. 
 The CBE-0 supplement regulations “allow application holders to comply with the 
requirement to update labeling promptly to include a warning about a clinically significant 
hazard as soon as there is reasonable evidence of a causal association with a drug . . . .”30 
According to the 2008 amended regulations governing the CBE-0 process, a CBE-0 labeling 
supplement is appropriate only to show new information.  The 2008 amendments clarified that 
the supplement may be used to “add or strengthen a contraindication, warning, precaution, or 
adverse reaction only if there is sufficient evidence of a causal association with the approved 
product.”31  The FDA reviews all labeling changes proposed in a CBE-0 supplement and the 
underlying data and research supporting the change.  The FDA then accepts, rejects, or requests 
modifications to the proposed changes as deemed appropriate, and can bring enforcement action 
if the information makes the product’s label false or misleading.32  Also, if the newly acquired 
information causes the product to no longer meet FDA standards, the agency can take action by 
rescinding the drug’s approval.33   
                                                          
28 Id., See also 21 C.F.R. §§ 314.70(c) (6) (iii) and 601.12(f) (1). 
29 See 21 U.S.C. 505(o)(2)(C) 
30 See 78 Fed. Reg. 67985, see also 21 C.F.R. 201.57(c). 
31 Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products, 78 Fed. 
Reg. 67985-02 (proposed Nov. 13, 2013) (to be codified at 21 C.F.R. pt. 314 and 601). 
32 See 21 U.S.C. 352(a). 
33 See 21 U.S.C. 355(e), 355-1. 
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B. The 2012 Enactment of FDASIA/GDUFA: Paving the way for Generic Label Updating? 
 
In 2010, seventy-eight percent of pharmaceutical prescriptions were filled with generic 
brands.34  Today, the top ten drugs filled in America are all generic brands.35  Over the past 
decade, generic drugs have provided a savings of over $824 billion dollars to the nation’s health 
care system in the last decade.36  In response to the rapid growth of generic drugs over the past 
decades, Congress, in 2012, enacted the Generic Drug User Fee Act (“GDUFA”) as a part of the 
Food and Drugs Administration Safety and Innovation Act (“FDASIA”).37  GDUFA allows for 
more speed in approving generic drugs while ensuring safety and low costs by requiring generic 
manufacturers to pay fees to supplement the costs of reviewing generic drug applications and 
inspecting facilities.38  As the FDA has explained “Recognizing the critical role generic drugs 
play in providing more affordable, therapeutically equivalent medicine, the Generic Drug User 
Fee program is designed to keep individual fee amounts as low as possible to supplement 
appropriated funding to ensure that consumers continue to receive the significant benefits offered 
by generic drugs…”39  
The FDASIA gives the FDA the authority to collect user fees from the pharmaceutical 
industry to “fund reviews of innovator drugs, medical devices, generic drugs and biosimiliar 
                                                          
34 Gary Gatyas, IMS Institute Reports U.S. Spending on Medicines Grew 2.3 Percent in 2010, to $307.4 Billion, IMS 
HEALTH (April 19, 2011), http://www.imshealth.com/vgn-ext-templating/ 
v/index.jsp?vgnextoid=1648679328d6f210VgnVCM100000ed152ca2RCRD. 
35 von Koeckritz, Karen.  Generic Drug Trends- What’s Next? (April 11, 2012), http://www.pharmacytimes.com 
/publications/issue/2012/April2012/Generic-Drug-Trends-Whats-Next. 
36 Generic Drug User Fee Act Program Performance Goals and Procedures, (Nov. 10, 2014), available at 
http://www.fda.gov/downloads/ForIndustry/UserFees/GenericDrugUserFees/UCM282505.pdf 
37 Fact Sheet, supra note 1. 
38 Generic Drug User Fee Amendments of 2012.  U.S. Food and Drug Administration, (Nov. 10, 2014), available at 
http://www.fda.gov/ForIndustry/UserFees/GenericDrugUserFees/default.htm.  See 112 H.R. 3988, 2012 H.R. 
3988,112 H.R. 3988. 
39 Supra note 35. 
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biological products.”40  The FDASIA also encourages innovation by providing a “breakthrough 
therapy” designation for certain drugs that may be substantially superior to current drugs on the 
market.  This designation would allow for an expedited review and approval process through the 
collection of fees to create additional resources.41  The FDASIA was also implemented to protect 
the drug supply chain and to ensure patients have access to drugs they need by extending the 
FDA’s detention authority and increasing penalties for adulterated and counterfeit drugs.42 
The purpose of the GDUFA is to increase safety by requiring that any manufacturer who 
participates in the U.S. generic drug industry be inspected biennially.43  It also will “deliver 
greater predictability and timeliness to the review of generic drug applications, slashing review 
times and saving industry time and money.”44  The GDUFA also requires that any domestic or 
international facility involved in the manufacture of generic drugs and their ingredients be 
identified upon their sale in the United States to increase transparency in the complex, global 
pharmaceutical market.45  All facilities and companies selling generic drugs must register 
annually with the FDA.46  This includes manufacturers of active pharmaceutical ingredients 
whose products may be used in US products through another manufacturer or facility that 
repackages generic drugs.47  The FDA has laid out guidance on which companies need to self-
identify and what information they are required to provide to the FDA.48  In its guidance 
                                                          
40 Food and Drug Administration Safety and Innovation Act (FDASIA), (Jan. 1, 2015), available at 
http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmen
dmentstotheFDCAct/FDASIA/ 
41 Id. 
42 Id. 
43 Supra note 35. 
44 Fact Sheet, supra note 1. 
45 Id. 
46 112 H.R. 3988.  See also Gaffney, Alexander.  FDA Releases Guidance on Facility Registrations, Payments under 
GDUFA, (Jan. 21, 2015), http://www.raps.org/regulatoryDetail.aspx?id=7435. 
47 Id. 
48 Id. 
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documents, the FDA explained that “[t]he information provided through self-identification will 
enable quick, accurate and reliable surveillance of generic drugs and facilitate inspections and 
compliance.”49 
The GDUFA also aims to cut down the review time of generic drug applications from 
thirty-one months to about ten months.  The funds collected from the user fees, which is stated to 
be one half of one percent of generic drug sales, will be used to assess the safety of generic 
drugs.50 
The user fees result in benefits to the public health by financing the FDA to carry out 
functions that it could not do previously.  By cutting the review time of a generic drug 
applications, the GDUFA will increase savings in development time, while decreasing the costs 
of bringing a generic drug to the market.51  Therefore, this may also result in a decline in costs to 
consumers.52 
C. Recent Supreme Court Cases 
Recent Supreme Court cases have addressed the issue of whether generic drug 
manufacturers should be liable for failing to provide adequate warnings on drug labels.53  This 
wave of lawsuits began with Wyeth v. Levine in 2009. 54 
                                                          
49 Id. 
50 Sullivan, Thomas.  The Food and Drug Administration Safety and Innovation Act (FDASIA): Summary of 
GDUFA, MDUFA, BsUFA and Pediatrics, POLICY AND MEDICINE (NOV. 10, 2014), 
http://www.policymed.com/2012/07/the-food-and-drug-administration-safety-and-innovation-act-fdasia-summary-
of-gdufa-mdufa-bsufa.html 
51 Supra note 26. 
52 Id. 
53 Woodcock, supra note 13. 
54 Wyeth v. Levine, 555 U.S. 555 (2009) 
11 
 
In Wyeth, the patient was injured by using a brand-name anti-nausea drug through an IV-
push method.  The patient claimed the drug’s label was defective because it failed to instruct 
clinicians to use an IV-drip method, rather than the higher-risk push method.55  The patient filed 
a failure-to-warn suit in state court against the drug manufacturer, Wyeth for failing to update the 
product’s label with newly acquired safety information, even though the labels conformed to 
FDA regulations.56 
The Supreme Court determined that federal law does not preempt a state law failure to 
warn claim for brand name drugs.57  The Court explained that “[i]t has remained a central 
premise of federal drug regulation that the manufacturer bears responsibility for the contents of 
its label at all times.”58  The court held that the manufacturer must create an adequate safety label 
and ensure it is up to date as long as the product is being sold.59  The Court opined “Wyeth failed 
to demonstrate that it was impossible for it to comply with both federal and state requirements . . 
. the mere fact that the FDA approved . . . [the] label does not establish that it would have 
prohibited such a change.”60  The Court held that Wyeth could have strengthened the warning 
labels under the FDA’s CBE-0 regulation to comply with state law.61  The Court’s holding in 
Wyeth sent a clear message to brand-name drug manufacturers that: “if they do not unilaterally 
                                                          
55 See Wyeth, 555 U.S. 555.  See also Boyd, Marie. Unequal Protection Under the Law: Why FDA Should Use 
Negotiated Rulemaking to Reform the Regulation of Generic Drugs, 35 Cardozo L. Rev. 1525, 1530 (2014). 
56Goldstein, Jacob.  Wyeth v. Levine: The Mother of All Preemption Cases, W.S.J. BLOGS (Nov. 9, 2014), 
http://blogs.wsj.com/health/2008/09/19/wyeth-v-levine-the-mother-of-all-preemption-cases/  
57 Supra note 13. 
58 Wyeth, 555 U.S. at 570-71. 
59 Id. 
60 Wyeth, 555 U.S. at 573. 
61 Boyd, supra note 55. 
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strengthen their labels when they know it is necessary, they will face liability in the state court 
system.”62 
In 2011, the Supreme Court distinguished Wyeth in the subsequent case PLIVA v. 
Mensing.63  In PLIVA, the patients alleged they developed tardive dyskinesia after using the 
generic drug metoclopramide.  The patients claimed the generic drug label did not contain 
adequate warnings of this adverse side effect.64  The manufacturer of the drug argued that: “(1) 
FDA regulations require the warnings on generic pharmaceuticals to be the same as those of the 
brand-name product; and (2) they had no ability to unilaterally add or strengthen warnings 
without FDA approval.”65  The Court agreed with the manufacturer, and held the claim was 
preempted because generic manufacturers cannot add further warnings without violating FDA 
regulations under the Hatch-Waxman Act.66   
The holdings in Wyeth and PLIVA suggest that “The Supreme Court has determined that 
generic manufacturer’s lack of independence with respect to drug safety labeling makes it 
impossible for them to comply with both Federal drug labeling requirements, and state tort law 
(failure-to-warn or design-defect) requirements.”67  The holdings in Wyeth and PLIVA suggest 
that access to the courts depends on whether a consumer purchased a generic or a brand-name 
drug.68 
                                                          
62 Sarah S. James, Note, Generic Drug Manufacturer Liability: Achieving a Balance Between Consumer 
Affordability and Safety, 38 Iowa J. Corp. L. 177, 182 (2013). 
63 See PLIVA, 131 S. Ct. 2567. 
64 Id.; Rose, Beth S., Charles J. Falletta & Vincent R. Lodato.  Pliva, Inc. v. Mensing–United States Supreme Court 
Holds That Failure To Warn Claims Against Generic Pharmaceutical Manufacturers Are Pre-Empted By Federal 
Law, N.L.R.  (Nov. 10, 2014), http://www.natlawreview.com/article/pliva-inc-v-mensing-united-states-supreme-
court-holds-failure-to-warn-claims-against-generic 
65 Id. 
66 Id. 
67 Thomas, supra note 4. 
68 Supra note 13. 
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In 2013, the Supreme Court decided Mutual Pharmaceutical Co. v. Bartlett.69  In Bartlett, 
the plaintiff suffered an adverse effect from taking the generic medication Sundilac.70  The 
patient, who took the prescribed medication to alleviate muscle pain, developed Stevens - 
Johnson syndrome and toxic epidermal necrolysis and became extremely disfigured as a result.71  
This side effect was originally listed as “a possible adverse reaction” on the safety label and was 
later moved to the “warnings” section of the generic label in conformance with the FDA’s 
recommendation.72 
The Supreme Court held in Bartlett that federal law preempts a state-law design-defect 
claim against a generic drug manufacturer under PLIVA.73  The Court first decided that New 
Hampshire does not have a “pure” design-defect cause of action, which would require a jury to 
balance the risks and benefits of an FDA approved drug to determine if it is “unreasonably 
dangerous”.74  As the FDA argued in its brief, this would undermine their assurance of approved 
drugs on a state-by-state and case-by-case basis, as well as Congress’s purpose that FDA 
approvals are made by experts applying science based judgment.75  The Supreme Court 
determined that New Hampshire’s design defect cause of action includes an evaluation of the 
adequacy of the label.76  Through the design-defect analysis, the Court determined that generic 
drug manufacturers should not be held accountable for failure-to-warn or design-defect claims 
                                                          
69 See Bartlett, 133 S. Ct. 2466. 
70 Id. 
71 Id. 
72 Wolfman, supra note 18. 
73 Bartlett, 133 S. Ct. 2466; Wolfman, supra note 18. 
74 Bartlett, 133 S. Ct. at 2470. 
75 Id.; Brief for the United States as Amicus Curiae, p. 25, Mutual Pharm. Co. v. Bartlett, 133 S. Ct. 2466 (2013). 
76 See Bartlett, 133 S. Ct. 2466. 
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because generic drug makers are not permitted to independently update safety information on 
drug labeling.77 
A recent case contesting the issue of generic drug liability has been decided by 
California’s highest court.78  Here, the plaintiff was injured from her prolonged use a generic 
form of Fosamax.79  She claimed Teva, the generic maker, had failed to update their warnings in 
compliance with the brand Fosamax’s warnings.80  The defense rebutted that the plaintiff’s claim 
was preempted by PLIVA.   The trial court held, and the appellate court affirmed, that since the 
brand-name drug maker made the safety update, the generics are at fault for failing to 
immediately update their labels to conform to the newly acquired information.81  This case raised 
issues about the scope of PLIVA and whether failure-to-update claims would be preempted by 
Federal law.82  The California Supreme Court declined to review the decision, therefore the 
pharmaceutical company appealed to the United States Supreme Court.83  The subsequent 
petition was denied, leaving the decision about generic drug liability to the FDA.84  The Supreme 
Court’s denial of the petition to hear this case may pave the way for similar failure to warn 
claims to be brought against generic drug makers in state court.85 
                                                          
77 Silverman, Ed.  Lawmakers Ask White House to Review FDA Rule for Generic Label Changes, PHARMALOT 
(Sept. 2, 2014), http://blogs.wsj.com/pharmalot/2014/06/26/lawmakers-ask-white-house-to-review-fda-rule-for-
generic-label-changes/. 
78 Teva Pharmaceuticals USA, Inc. v. Superior Court, 217 Cal. App. 4th 96 (Cal. App. 4th Dist. 2013). 
79 Id. 
80 Id. 
81 Silverman, Ed.  Supreme Court Declines to Review Case About Generic Labeling.  (Jan. 21, 2015).  PHARMALOT, 
http://blogs.wsj.com/pharmalot/2015/01/21/supreme-court-declines-to-review-case-about-generic-labeling/. 
82 Id. 
83 Id. 
84 Id. See also Teva Pharm. USA, Inc. v. Superior Court, 2015 U.S. LEXIS 687, 1 (U.S. Jan. 20, 2015). 
85 Kang, Y. Peter, High Court Lets Teva Drug Labeling Suit Go Ahead, LAW 360 (January 20, 2015), 
http://www.law360.com/articles/612895/high-court-lets-teva-drug-labeling-suit-go-ahead. 
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Similarly, the Alabama Supreme Court recently upheld a suit against brand name 
manufacturer for damages caused by the generic form under the concept of “innovator 
liability.”86  Here, the court found brand drugs could be liable because the generic manufacturers 
relied on the warnings and labels of the brand drug.87  The court relied on the holding in PLIVA, 
finding that the federal regulatory scheme made it foreseeable that the brand-name drug owed the 
generic version a duty of care.88  The pharmaceutical industry fears that this precedent could 
cause a damaging trend throughout the U.S. economy.89   
D. Proposed FDA Regulation 
Under the current federal regulations, a generic drug manufacturer may only use the 
CBE-0 supplement process to update its product labeling to conform to the approved safety label 
for the similar brand-name drug.90  A generic drug manufacturer may not independently file a 
CBE-0 supplement to the FDA in light of newly acquired safety information or unilaterally 
change label its product’s label to add information that is different from the brand-name drug’s 
label.91 
On November 13, 2013, the FDA proposed to add 21 C.F.R. 317.70(c) (8), which amends 
the current regulations and procedures that govern the ability to update and change generic drug 
safety labels.92  This proposed rule would allow generic drug manufacturers to independently 
                                                          
86 See Weeks v. Wyeth, Inc., No. 1101397, slip op. (Ala. Aug. 15, 2014). 
87 James W. Huston, Erin M. Bosman, and Julie Y. Park.  Weeks II: Innovator Liability Finds a Sweet Home in 
Alabama, CLIENT ALERT (August 20, 2014), http://www.mofo.com/~/ 
media/files/clientalert/2014/08/140820weeksIIInnovatorliability.pdf 
88 Id. 
89 The Threat of ‘Innovator Liability’, WALL ST. J. (March 13, 2013), available at 
http://www.wsj.com/articles/SB10001424127887323628804578346231780434760 
90 See 21 U.S.C. 355(j) (1)-(2). 
91 Id. 
92 Supra note 26.  
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submit CBE-0 supplements to update labels in light of newly acquired safety information, 
regardless of whether this information may differ from the warnings on the brand name drug.93  
The generic manufacturer would able to distribute updated safety labels after submitting a 
“changes being effected” (CBE-0) supplement to the FDA, as well as safety information 
supporting the change.94  The CBE-0 will also notify the maker of the listed drug of the newly 
acquired safety information.95 
To make updated safety information readily available to the public and to avoid 
confusion, the FDA proposed to establish a webpage where the FDA will post new safety 
information acquired from the CBE-0 supplements.96   
This proposed rule would allow a generic drug to display a label that is temporarily 
inconsistent with the labels of the listed drug.97  The FDA would then evaluate whether the 
change is justified and make a decision on the generic and listed drug change at the same time, 
and as a result, both drugs will have the same FDA approved label.98  After the FDA has 
approves the safety label change, there will be a thirty day time frame in which all drug 
manufacturers of the “same” drug will have to submit a CBE-0 supplement with conforming 
label changes.99   
The amended regulations would also permit generic drugs which no longer have a brand 
name counterpart to update their own labels.  Under current regulations, there is no technique to 
                                                          
93 Id. 
94 Id. 
95 Id. 
96 Id. 
97 Id. 
98 Press Release, U.S. Food and Drug Administration, FDA Takes Action To Speed Safety Information Updates on 
Generic Drugs (Nov. 8, 2013) http://fda.gov/newsevents/newsroom/pressannouncements/ucm374171.htm 
99 Supra note 22. 
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accomplish such label change, and therefore, these drugs are being sold on the market with 
potentially incorrect or out-of-date safety information.100  The FDA estimates approximately 420 
drugs are sold only in the generic form, and the listed drug is no longer manufactured.101  Current 
FDA regulations also prohibit a generic drug manufacturer from sending a “Dear Doctor” letter 
which would inform physicians of updated and new safety warning information.102 
Part III:  Reexamining the Current FDA Regulations to Permit Generic Drug 
Manufacturers to Update Safety Labels 
 
FDA-approved drug labeling provides patients with essential information needed for the 
safe and effective use of a drug, and reflects the FDA’s findings of the safety and effectiveness 
under the labeled conditions of use.103  Scholars argue that “[t]he primary purpose of labeling for 
prescription drugs is to provide health care practitioners with the essential scientific information 
needed to facilitate prescribing decisions, thereby enhancing the safe and effective use of 
prescription drug products and reducing the likelihood of medication errors.”104  This safety 
information is used by practitioners and patients to make decisions about prescription drugs by 
weighing the stated risks against the benefits.105 
As of 2010, nearly 90% of pharmaceuticals in the United States are filled with a generic 
brand despite the availability of a substitute.106  Despite the changes in the market, and the 
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evolution of the generic drug industry, the regulations concerning generic labeling have 
remained largely unchanged.107 
Generic drug makers may not always be able to quickly inform consumers of updated safety 
information, because they are not able to act under the same authority as their brand name 
counterparts.108  Generic drugs must maintain an identical label to their brand-name substitutes, 
and are only required to update safety labels when the brand name has filed a CBE Supplement 
with the FDA and the change has been approved.109  
A. Public Policy Favors Informing Patients and Physicians of Changes in Drug Safety 
Information 
 
The side effects and risks of taking a particular drug may not come to light until after the 
drug has been approved by the FDA.110  Therefore, both brand name and generic makers are 
required to have written procedures for the review, surveillance and reporting of adverse drug 
information, and any “serious and unexpected” drug experiences to the FDA.111  Information 
obtained from any source, foreign or domestic, or any type of post-marketing study or 
investigation must be reviewed.112  Both brand-name and generic manufacturers must comply 
with postmarking reports by submitting an annual report to the FDA including a summary of 
information that may affect the drug’s safety, effectiveness, or labeling, as well as a description 
of the actions taken in response to the new information and proposed revisions to the safety 
labels.113 
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The Supreme Court ruling in PLIVA sparked the concern that generic labels are not 
sufficient to warn consumers of the risks associated with medications.114  Public policy favors 
informing health care practitioners and patients of safety information regarding the prescription 
medications.  The public will benefit as a result of manufacturers updating drug safety labels in 
response to newly acquired safety information.115  Allison Zieve, head of the litigation group at 
Public Citizen, commented “[n]o drug is safe in all situations. A drug is safe when used in 
accordance with labeling that accurately reflects the known risks. The sooner generic drug 
companies are allowed to make safety updates, the better for public health.”116  The public is 
harmed when a regulatory delay allows a safety gap and relevant information is not readily 
available to the affected parties.117  The ability to update safety information ensures that patients 
have the most recent and reliable information about their medications, and can make an informed 
choice on whether to take a prescribed drug.   
The proposed amendments to current FDA regulation will permit generic drug makers to 
update product labeling to “reflect data obtained through post-market surveillance.”118  Although 
the proposed amendment does not require generic manufactures to conduct new clinical tests, it 
will allow the manufacturers to inexpensively update labels when adverse information is 
received and investigated while keeping prices lower than brand-name counterparts.119  Some 
argue prices will increase due to the liability generic drug makers would face.120  However, 
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proponents believe generic drug makers will not face an increase in litigation because lawsuits 
would be less likely to occur when generic drugs are able to update safety information, 
preventing injury from occurring altogether.121  The FDA states the proposed regulation will 
“provide incentive to generic drug companies to actively participate with the FDA in ensuring 
the timeliness, accuracy and completeness of drug safety labeling.”122 
“This proposal will help equip health care providers and consumers who depend on 
generic drugs with the best possible information to avoid adverse outcomes.”123  The public will 
benefit because both brand-name and generic drug makers will have the obligation to give 
doctors and patients the information necessary to avoid injuries.124  Through this amendment, the 
FDA will not only be able to preserve the principal of “sameness” between brand-name and 
generic drugs, but will also allow patients to have better information of a drug’s potential risks 
and benefits, regardless of the manufacturer.125   
Many opponents of the regulations claim that the time period where labels may differ will 
cause confusion and lead to over-warning.126  However, under the current regulations when a 
brand-name drug has a safety label update, it can take several months before the generic drug 
manufacturers updates their labels with the new warnings.127  Also, brand-name drugs have had 
                                                          
121 Id. 
122 Neger, Peter C., FDA Proposes New Change to Generic Labeling Rule, (Nov. 13, 2013), 
http://www.martindale.com/ products-liability-law/article_Bingham-McCutchen-LLP_2028576.htm 
123Statement of Senator Matthew Cartwright, Press Release, U.S. Senate Committee on Health, Education, Labor, & 
Pensions, Harkin Welcomes FDA’s Release of Proposed Rules to Protect Consumers Using Generic Drugs (Nov. 8, 
2013) available at http://www.help.senate.gov/newsroom/press/release/?id=fdadb26d-2999-4a09-9766-
a2a2f7546701. 
124 Press Release, U.S. Senate Committee on Health, Education, Labor, & Pensions, Harkin Welcomes FDA’s 
Release of Proposed Rules to Protect Consumers Using Generic Drugs (Nov. 8, 2013) available at 
http://www.help.senate.gov/newsroom/press/release/?id=fdadb26d-2999-4a09-9766-a2a2f7546701.  
125 Id. 
126Zieve, supra note 101. 
127 Id. 
21 
 
the ability to update their own safety labels for over thirty years, and there has never been a 
problem with over warning of safety information.128 
The confusion concerning the temporary differences in brand and generic labels will be 
outweighed by the benefit to public health.129  Dr. Janet Woodcock, director of the FDA's Center 
for Drug Evaluation and Research stated “It is expected that a valid safety concern regarding a 
generic drug product also would generally warrant submission of a supplement for change to the 
labeling by the application holder for the corresponding brand drug, as well as other generic drug 
application holders.”130  Therefore, it can be assumed when new safety information is acquired, 
all manufacturers will apply to change the label, reducing the amount of differing labels even 
before the FDA has approved the change.  Further, the FDA will maintain a website tracking 
CBE-0 supplements so health care providers and patients will have access to the newest changes 
and updates.  Once the FDA approves a CBE-0 supplement, it will continue to be posted on the 
site, and a thirty-day timeframe will be established for drug manufacturers to submit a CBE-0 
supplement conforming to the label change.131  This will cut down the amount of time differing 
labels will be available on the market.132  Under the FD&C Act the FDA is authorized to “require 
and, if necessary [order] labeling changes if FDA becomes aware of new safety information that 
FDA believes should be included in the labeling of the drug.”133  Therefore, the FDA can 
implement a rule allowing generic drugs to independently update warning labels, ensuring the 
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newest warnings are available to consumers regardless of whether they take brand name or 
generic medication. 
Senator Henry Waxman, co-author of the 1984 Hatch-Waxman Act, argued that allowing 
generic drugs to update their labels will ease customers’ concerns about the danger of taking 
generic drugs because they will be aware of the latest risks and safety information. Waxman 
further argued it will aid in preventing consumers from believing generic drugs are not as safe as 
brand name drugs because generics will have more incentive to warn consumers about safety 
issues and will be able to get the information out to consumers.134  Generic drug manufactures 
have already proven that generic drugs are equally as safe as the brand-name counterpart and the 
FDA has agreed.135  Gary Beuhler, Director of the FDA’s office of Generic Drugs argued 
“[m]ost people believe that if something costs more, it has to be better quality.  In the case of 
generic drugs, this is not true.  The standards for quality are the same for brand name and generic 
products.”136 
As generic drugs’ market shares increase, brand name drugs lose incentive to engage in 
safety monitoring.137  Dr. Woodcock further argued “[t]he FDA cannot monitor all post-approval 
data by itself, drug safety is threatened when the regulatory and common-law incentives 
designed to motivate manufacturer diligence weaken with shifting control of market share.”138  
Because the generic drug has the majority of the market share, they will probably receive the 
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most reports concerning risks and adverse experiences using the drug.139  Generic manufacturers 
therefore may be in a better position to update product safety labels because they serve a larger 
amount of the population.140  Under the current system, the generic manufacturers cannot update 
safety information until the brand-name takes action.141 
Allowing generic drug manufacturers to independently update product safety labels in 
light of newly acquired safety information will be a great benefit to public health by increasing 
patient safety and awareness, while keeping costs and confusion at a minimum. 
B. Generic Drugs Will Continue to be an Affordable Alternative to Brand-Name Prescriptions 
 
Generic drugs are more affordable because manufacturers do not need to spend money on 
costly clinical trials.  Even if generics had more responsibility under the proposed regulation, the 
savings would still be apparent.142  The proposed rule would assist in keeping liability costs 
down by preventing injuries from occurring in the first place through efficient safety label 
updates.143   
Currently, generic drugs are shielded from liability because they cannot update their 
labels.  If a generic drug maker becomes aware of a risk, they cannot change safety labels unless 
the brand name does so.   
Critics of the proposed regulation fear that allowing generic drug makers to update their 
product safety labels will open them up to failure-to-warn lawsuits.144  However, if the injuries 
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had never occurred, there would be no law suit.145  Allison Zieve of Public Citizen testified in 
front of the House of Representatives Subcommittee on Health: 
Because immunizing the companies from liability does not make the 
injured patients’ costs go away. The medical expenses and lost 
wages from lost work time still exist; they are carried by the patients, 
health insurers, and taxpayers, through Medicare or Medicaid. 
Because the proposed rule will give generic manufacturers the tools 
and incentive to update safety labeling, any costs of the rule should 
be offset by cost savings—savings in medical care for the patients 
who will not be injured because physicians and patients are armed 
with updated labeling about safety risks.146 
 
 
Critics also fear that generic may over-warn to avoid liability.  However, proponents have 
noted since the ruling in Wyeth there has not been a surge in CBE-0 supplements to update 
brand-name labels, therefore there should not be a worry for over warning by generic drug 
makers.147 
According to the FDA, "the main reason generic drug companies can market their drugs 
at lower prices is that they don't face the same development costs as brand-name companies."148  
Generic drugs are approved through an expedited process, and are permitted to skip costly 
clinical trials provided that the drug is the “same” and the “bioequivalent” of its brand-name 
counterpart.149  The proposed regulation does not place any new requirements for generic drugs 
to undergo separate clinical trials and testing, therefore the costs to consumers should remain 
low.150  Allison Zieve stated “[g]eneric competition [also] helps keep the cost of drugs down . . . 
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it also encourages the research based drug companies to keep finding new and better medicines 
that have patent protection.”151 
An estimate published by the consulting firm Matrix Global Advisors stated the 
proposed rule would lead to approximately a 5% annual increase in spending on generic 
drugs.152  The FDA has examined the economic impacts of the proposed regulation and has 
determined:  
the proposed rule would only impose new burdens on small generic 
drug manufacturers who submit CBE-0 supplements for safety-
related labeling changes.  The FDA believes the impact will not be 
significant due to the low-cost of submission, and the uncertainty of 
the amount of supplements that may be filed.153 
 
C. Allowing Generic Drug Makers to Update Product Safety Labels will Provide a Means for 
Generic Drugs which no Longer have a Brand Name Counterpart to Make Safety Updates 
 
The FDA estimates there is approximately 420 drugs that are sold only in the generic 
form.154  The Generic Pharmaceuticals Association states that number is even larger, estimating 
that about 45% of generic drugs have no brand-name counterpart.155  There is a gap in the current 
regulatory system for generic drugs whose brand-name drug counterpart is no longer sold on the 
market.  Since a brand name drug is only permitted to update safety warnings on product labels, 
the generic drugs that no longer have a brand-name counterpart are left without a means of 
updating safety label information.156  Currently, there are no clear and efficient methods to 
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disseminate information to health care providers as well as the public about newly discovered 
safety risks.157 
This is concerning because serious drug risks may not be identified until after the generic 
drug enters the market, and several generic drugs no longer have a corresponding brand-name 
drug on the market.158  Without a corresponding brand-name drug, there are no available 
resources to conduct on-going investigations as to the safety of the drug.159  Therefore, drugs that 
are only available in generic form are not being continuously monitored and investigated, and 
there is no way to update the drug’s label if new safety information were to come to their 
attention. 
Part IV:  Conclusion 
 
The FDA has acknowledged the growth of the generic pharmaceutical industry, and its 
impact on the United States’ health industry.  Today, generic drugs fill almost 90% of all 
pharmaceuticals in the United States, yet consume only 27% of total drug spending, resulting in 
huge savings to American consumers every year.160 
The Hatch-Waxman Act of 1984 allowed for generic drugs to be approved through an 
abbreviated process, provided the generic drug was the “same” in ingredients, dosage, and 
administration, and was the “bioequivalent” of the brand-name drug.161  The enactment led to a 
greater number of generic drug approvals, and millions of dollars of savings in drug costs to 
American consumers.162 
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The FDASIA and GDUFA were enacted in 2012 in response to the emerging generic 
drug industry.  The GDUFA was enacted to increase safety and accessibility of generic drugs, 
and provide transparency by inspecting all generic drug facilities.163  The Act was designed to 
expedite the approval process of generic drugs, and as a result, cut down the backlog of pending 
approvals.164  As generic drugs continue to take an increasing amount of market share, the 
government has responded by imposing similar burdens and benefits on generics as brand name 
drugs through GDUFA.  Allowing generic drugs to file CBE-0 changes and update labels would 
conform to this emerging trend. 
The proposed regulation to permit generic drug manufacturers to update their safety 
labels without FDA approval, and independent of the brand-name drug’s label will result in an 
increase of safety information that is beneficial to public health.  Patients and physicians will be 
up to date with the newest safety information concerning generic drugs, which are used by the 
majority of Americans today. 
Although this may create temporary differences between generic and brand-name drug 
labels, it will increase patient safety overall.  Allowing generic drug manufacturers to 
independently update safety labels will also encourage them to monitor and research the safety of 
marketed drugs.  It may also increase the quality of the drugs being manufactured by creating 
liability for generic products.   
Updating the FDA’s current regulations will also create an opportunity for generic drugs 
that no longer have a brand-name counterpart to keep patients up-to-date on the newest safety 
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information, and provide a consistent method for updating safety labels for all drugs and 
prescriptions in the United States. 
